Breast Cancer

Evidence-based overview of itraconazole in metastatic triple-negative breast cancer, including early clinical signal and anti-angiogenic biology

Itraconazole has combination-treatment interest in metastatic triple-negative breast cancer, but the evidence remains early. The main signal comes from a small retrospective series, supported by anti-angiogenic and pathway-based preclinical data.

Overview

The breast-cancer rationale comes mainly from itraconazole's effects on angiogenesis, hypoxia-relevant biology, and aggressive phenotypes such as TNBC.

Key human data

A small Japanese retrospective series evaluated itraconazole in 13 heavily pre-treated patients with recurrent TNBC, most with visceral metastases.
Itraconazole was used alongside chemotherapy, typically in continuous oral dosing ranges such as 200 to 400 mg daily, rather than a clearly established pulsed breast-cancer schedule.
Reported outcomes included median progression-free survival of about 10.8 months and median overall survival of about 20.4 months.
These findings were promising, but there was no randomised comparator arm, so the data remain hypothesis-generating.

Key preclinical data

Itraconazole has shown anti-proliferative effects in breast-cancer cell lines, including TNBC models.
In non-TNBC breast-cancer models such as MCF-7 and SKBR-3, itraconazole inhibits the Hedgehog pathway by lowering SHH and GLI1 activity. This increases cancer-cell death and pushes the cells toward autophagy. In mice, this translated into smaller tumour grafts and more cell death in the tumours.
In TNBC models, the best-described mechanism is suppression of the AKT/mTOR signalling pathway. This slows cell growth, reduces colony formation, and makes the cells less able to move and spread.
The broader breast-cancer and pan-cancer literature still supports Hedgehog as one of itraconazole's relevant cancer pathways, even if the TNBC paper itself focuses more on AKT/mTOR and cell-cycle effects.
Animal and translational work also supports anti-angiogenic activity, with itraconazole affecting blood-vessel growth and pro-angiogenic factors.
Itraconazole has hypoxia-relevant and anti-angiogenic effects, but direct HIF inhibition is better established for other agents such as mebendazole than for itraconazole itself.

Practical interpretation

This remains a very early evidence area. The biology is plausible, and the retrospective TNBC signal is worth noting, but itraconazole is still an experimental off-label approach, not a standard breast-cancer treatment.

Any clinical use needs careful review of CYP3A4 interactions, QT risk, hepatic function, and the wider treatment regimen.

References

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.